Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 2, 2016

View Archived Issues

Vimpat launched in Japan as adjunctive therapy for partial onset seizures

AstraZeneca and Aspen complete anesthetics commercialization agreement

FDA grants fast track designation to APL-130277 to treat off episodes in Parkinson's disease

Pfizer presents data on new JAK1/TYK2 inhibitor

Genetech discloses KDM5 inhibitors for the potential treatment of cancer

Genentech describes new CREB-binding protein inhibitors

Shanghai De Novo Pharmatech patents IDO1 and/or TOD2 inhibitors

Genentech and Roche disclose TRPA1 antagonists

Enanta Pharmaceuticals describes FXR agonists

Merck & Co. develops retinoid RORgammaT antagonists

Incyte announces PI3Kgamma inhibitors

Johns Hopkins and Salk co-lead an initiative to advance bipolar disorder and schizophrenia research

PCI Biotech and BioNTech establish preclinical research collaboration

FDA approves Blincyto for pediatric patients with Ph-negative B-cell precursor ALL

FDA awards fast track designation to aducanumab in Alzheimer's disease

Omecamtiv mecarbil enters phase III clinical development

Chugai transfers the manufacturing and marketing rights for Vesanoid

Myriad Genetics completes Assurex Health acquisition

AdAlta receives grant for the development of AD-114 in IPF

FDA accepts Array's NDA for binimetinib

Lytix's LYX-315 studied at Massachusetts General Hospital and Harvard Medical School

BARDA selects Takeda Vaccines for the development of Zika vaccine

European Commission approves expanded use of Xultophy

Alnylam's ALN-AS1 receives FDA orphan drug designation

TLR4 expression predicts response to immunosuppressive therapy in patients with myocarditis

University of Dundee, GlaxoSmithKline develop novel compound for leishmaniasis

New microRNAs linked to 10-year risk of fatal myocardial infarction

Genmab wins sBLA for ofatumumab in CLL

SAGE-217 shows promise for seizure disorders

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 5, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
Study identifies CAND1 as therapeutic target in hepatoblastoma
BioWorld Science
Hepatoblastoma is the most common liver cancer during childhood, with limited therapeutic options in aggressive or relapsed cases. NEDDylation is a...